Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025002083> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3025002083 endingPage "95" @default.
- W3025002083 startingPage "90" @default.
- W3025002083 abstract "To evaluate the safety and efficacy of intravitreal Bevacizumab in treatment of non-ischemic macular edema secondary to retinal vein obstruction (RVO).A 2-year-retrospective study was performed on 26 patients hospitalized for non-ischemic macular edema secondary to RVO. All the patients underwent a complete ophthalmologic exam, with best corrected visual acuity (BCVA) testing, fundus photography, fluorescein angiography (FA) and macular thickness measurement by optical coherence tomography (OCT). Reevaluation was performed monthly for VA, OCT, and ophthalmoscopy and, at every 3 months, by FA. A standard protocol of 0.05 ml intravitreal Bevacizumab injection was applied. Further administrations were performed according to clinical evolution.The medium follow-up period was of 9,7 months (6-20 months). There were no significant complications following the procedure. The number of intravitreal Bevacizumab injections varied from 2-5/ patient. All the patients experienced an improvement in VA and a significant regression of macular edema. The smallest number of intravitreal Bevacizumab injections and the best visual prognosis were observed in cases with branch retinal vein obstruction (BRVO) and early presentation (p<0.05).As a pathogenic therapy, intravitreal Bevacizumab is a safe, repeatable procedure and it may be considered an effective and lasting treatment for non-ischemic macular edema secondary to RVO. Intravitreal Bevacizumab should be included in the therapeutic protocol of RVO, both for early and delayed presentations. Abbreviations: RVO = retinal vein obstruction, BRVO = branch retinal vein obstruction, CRVO = central retinal branch obstruction, BCVA = best corrected visual acuity, FA = fluorescein angiography, OCT = optical coherence tomography." @default.
- W3025002083 created "2020-05-21" @default.
- W3025002083 creator A5002322873 @default.
- W3025002083 creator A5011527899 @default.
- W3025002083 creator A5023033400 @default.
- W3025002083 creator A5047147380 @default.
- W3025002083 creator A5063776536 @default.
- W3025002083 date "2016-04-01" @default.
- W3025002083 modified "2023-10-18" @default.
- W3025002083 title "Off-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions." @default.
- W3025002083 cites W1965030185 @default.
- W3025002083 cites W1972082824 @default.
- W3025002083 cites W1981783036 @default.
- W3025002083 cites W2015393810 @default.
- W3025002083 cites W2033843345 @default.
- W3025002083 cites W2058312539 @default.
- W3025002083 cites W2069220590 @default.
- W3025002083 cites W2069987569 @default.
- W3025002083 cites W2076843885 @default.
- W3025002083 cites W2078040311 @default.
- W3025002083 cites W2081275070 @default.
- W3025002083 cites W2104689293 @default.
- W3025002083 cites W2138489082 @default.
- W3025002083 cites W2315896448 @default.
- W3025002083 cites W2608488415 @default.
- W3025002083 cites W2949332406 @default.
- W3025002083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5711371" @default.
- W3025002083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29450329" @default.
- W3025002083 hasPublicationYear "2016" @default.
- W3025002083 type Work @default.
- W3025002083 sameAs 3025002083 @default.
- W3025002083 citedByCount "1" @default.
- W3025002083 countsByYear W30250020832022 @default.
- W3025002083 crossrefType "journal-article" @default.
- W3025002083 hasAuthorship W3025002083A5002322873 @default.
- W3025002083 hasAuthorship W3025002083A5011527899 @default.
- W3025002083 hasAuthorship W3025002083A5023033400 @default.
- W3025002083 hasAuthorship W3025002083A5047147380 @default.
- W3025002083 hasAuthorship W3025002083A5063776536 @default.
- W3025002083 hasConcept C118487528 @default.
- W3025002083 hasConcept C141071460 @default.
- W3025002083 hasConcept C2776694085 @default.
- W3025002083 hasConcept C2777802072 @default.
- W3025002083 hasConcept C2778257484 @default.
- W3025002083 hasConcept C2780248432 @default.
- W3025002083 hasConcept C2780261187 @default.
- W3025002083 hasConcept C2780347916 @default.
- W3025002083 hasConcept C2780827179 @default.
- W3025002083 hasConcept C2908732032 @default.
- W3025002083 hasConcept C71924100 @default.
- W3025002083 hasConceptScore W3025002083C118487528 @default.
- W3025002083 hasConceptScore W3025002083C141071460 @default.
- W3025002083 hasConceptScore W3025002083C2776694085 @default.
- W3025002083 hasConceptScore W3025002083C2777802072 @default.
- W3025002083 hasConceptScore W3025002083C2778257484 @default.
- W3025002083 hasConceptScore W3025002083C2780248432 @default.
- W3025002083 hasConceptScore W3025002083C2780261187 @default.
- W3025002083 hasConceptScore W3025002083C2780347916 @default.
- W3025002083 hasConceptScore W3025002083C2780827179 @default.
- W3025002083 hasConceptScore W3025002083C2908732032 @default.
- W3025002083 hasConceptScore W3025002083C71924100 @default.
- W3025002083 hasIssue "2" @default.
- W3025002083 hasLocation W30250020831 @default.
- W3025002083 hasOpenAccess W3025002083 @default.
- W3025002083 hasPrimaryLocation W30250020831 @default.
- W3025002083 hasRelatedWork W1967122471 @default.
- W3025002083 hasRelatedWork W1993046207 @default.
- W3025002083 hasRelatedWork W2034589983 @default.
- W3025002083 hasRelatedWork W2089952742 @default.
- W3025002083 hasRelatedWork W2123772048 @default.
- W3025002083 hasRelatedWork W2130940350 @default.
- W3025002083 hasRelatedWork W2321207693 @default.
- W3025002083 hasRelatedWork W2734710580 @default.
- W3025002083 hasRelatedWork W3201356743 @default.
- W3025002083 hasRelatedWork W3350394 @default.
- W3025002083 hasVolume "60" @default.
- W3025002083 isParatext "false" @default.
- W3025002083 isRetracted "false" @default.
- W3025002083 magId "3025002083" @default.
- W3025002083 workType "article" @default.